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Abstract
Background: Cholesterol ester storage disease (CESD) is an autosomal recessive illness that
results from mutations in the LIPA gene encoding lysosomal acid lipase. CESD patients present in
childhood with hepatomegaly and dyslipidemia characterized by elevated total and low-density
lipoprotein cholesterol (LDL-C), with elevated triglycerides and depressed high-density lipoprotein
cholesterol (HDL-C). Usual treatment includes a low fat diet and a statin drug.
Results: In an 18-year old with CESD, we documented compound heterozygosity for two LIPA
mutations: a novel frameshift nonsense mutation and a deletion of exon 8. The patient had been
treated with escalating doses of lovastatin for ~80 months, with ~15% decline in mean LDL-C. The
addition of ezetimibe 10 mg to lovastatin 40 mg resulted in an additional ~16% decline in mean LDL-
C.
Conclusion: These preliminary anecdotal findings in a CESD patient with novel LIPA mutations
support the longer term safety of statins in an adolescent patient and provide new data about the
potential efficacy and tolerability of ezetimibe in this patient group.
Background
Cholesteryl ester storage disease (CESD; MIM 278000) is
an autosomal recessive disorder caused by a deficiency of
lysosomal acid lipase (LAL; acid cholesteryl hydrolase; EC
3.1.1.13). LAL is responsible for the intralysosomal
hydrolysis of cholesteryl esters (CE) and triglycerides (TG)
[1]. Patients with CESD present in childhood with
hepatomegaly, hypercholesterolemia and hypertriglyceri-
demia; most are diagnosed by age 20 [1]. Reduced LAL
activity is detectable in peripheral blood leukocytes, cul-
tured skin fibroblasts and liver homogenates [1]. More
recently mutational screening of the human LAL gene
(LIPA) [2-4] has been used for diagnosis. Wolman disease
(WD; MIM 278000) also results from mutations in LIPA.
WD is characterized by early death (usually before age 6
months) and widespread intracellular storage of both CE
and TG, mainly in liver, adrenal glands and intestine [1].
In vitro catalytic activity was decreased ~200-fold in WD
fibroblasts, but only ~50-fold in CESD fibroblasts [5],
showing correlation with the differences in phenotypic
severity [6,7].
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Defective LAL activity results in decreased free intracellu-
lar cholesterol [6,7]. Because intracellular free cholesterol
normally inhibits 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) reductase, cholesterol biosynthesis is
increased in CESD patients. Thus, pharmacological inhi-
bition of HMG-CoA reductase with statins would seem to
be a reasonable approach to restrain the increased choles-
terol biosynthesis in CESD. While the plasma lipoprotein
response to statins among CESD patients has been varia-
ble [8-14], these drugs are considered to be the anti-dysli-
pidemia agents of choice in CESD.
Ezetimibe is a novel type of lipid-lowering medication
that prevents the absorption of cholesterol and plant ster-
ols at the small intestinal brush border by interfering with
the activity of the NPC1L1 receptor [15-18]. Ezetimibe has
been used in adult hypercholesterolemic patients either as
monotherapy [19] or in combination with statins [20-25].
The rates of myopathy and serum transaminase elevations
in ezetimibe-treated patients appeared to be comparable
to those in placebo-treated patients [19-25]. We now
present our experience with the combination of lovastatin
and ezetimibe treatment in an 18 year old male with
CESD.
Results
Patient history
A three-year old boy presented to his paediatrician for
assessment of a pruritic abdominal rash. His birth and
infancy had been unremarkable, with normal growth and
development. There was no consanguinity; both parents
and two older sisters were all healthy. At age 3, hepat-
osplenomegaly was noted on abdominal examination
and was confirmed by ultrasound. No diagnosis was
made and he was monitored periodically. At age 8, he was
admitted to the hospital with gastroenteritis. Light micro-
scopy of a liver biopsy showed increased intracytoplasmic
glycogen and small lipid droplets in hepatocytes. Electron
microscopy showed membrane-bound lipid droplets with
small electron dense granules. A working diagnosis of gly-
cogen storage disease type III (DeBrancher disease) was
made, but skin fibroblast Debrancher activity was normal.
At age 10, hepatomegaly persisted and a second liver
biopsy was taken. Light microscopy showed altered lobu-
lar architecture of the hepatic parenchyma with distended
hepatocytes containing cytoplasmic granules and vacu-
oles with mild periportal fibrosis. Fibroblast acid lipase
activity was found to be 7% of normal, confirming the
diagnosis of CESD. Plasma concentrations of total choles-
terol (TC), triglycerides (TG), low-density lipoprotein
cholesterol (LDL-C) were each above the 95th percentile
for age and sex at 7.49, 3.23 and 5.59 mmol/L, respec-
tively, while plasma high-density lipoprotein cholesterol
(HDL-C) was below the 5th percentile at 0.46 mmol/L; he
had combined hyperlipidemia (hypercholesterolemia,
hypertriglyceridemia, hypoalphalipoproteinemia and
hyperbetalipoproteinemia). After 12 months, a low fat
diet was started (Figure 1).
After 6 months of diet alone, lovastatin 10 mg daily was
added. Because of rising plasma concentrations of TC and
LDL-C, the dose of lovastatin was increased to 20 mg after
~22 months and increased again to 40 mg after a further
~8 months. Ezetimibe 10 mg per day was added after a
further ~40 months and the combination of lovastatin 40
mg and ezetimibe 10 mg daily has continued for 12
months. Serum asparagine transaminase (AST) and creat-
ine kinase (CK) were measured concurrently with the
lipoproteins.
The proband's lipoprotein profile since age 10 is summa-
rized in Figure 1. Mean ± standard deviation (SD) lipopro-
tein concentrations on each phase of treatment were
determined from a minimum of three values. From base-
line concentrations, the diet was associated with a 5.3%
decrease in TC (6.67 ± 0.79 to 6.32 ± 0.26 mmol/L), a
27.3% decrease in TG (2.75 ± 0.48 to 1.99 ± 0.50 mmol/
L), a 2.2% increase in LDL-C (4.63 ± 0.77 to 4.73 ± 0.53
mmol/L), a 7.8% increase in HDL-C (0.64 ± 0.12 to 0.69
Plasma lipoprotein responses to treatment Figure 1
Plasma lipoprotein responses to treatment. The graph 
shows plasma lipoproteins measured serially in the proband 
over ~96 months. Abbreviations: TC, total cholesterol; LDL-
C, low-density lipoprotein cholesterol; TG, triglycerides; 
HDL-C, high-density lipoprotein cholesterol; Diet, fat 
restricted to 30% of total calories, L10, L20 and L40 for lov-
astatin 10, 20 and 40 mg daily, respectively; E, ezetimibe 10 
mg daily.
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Nucleotide sequence analysis of LIPA Figure 2
Nucleotide sequence analysis of LIPA. The nucleotide sequences, codon numbers, single letter amino acid codes for the 
deduced protein sequence are shown in each panel. Panel A shows normal LIPA genomic sequence above and the sequence 
from the proband's genomic DNA below. The inserted nucleotide is indicated by the arrow and the shifted reading frame is 
suggested by the presence of two peaks at each position following the insertion. Panel B shows normal LIPA genomic sequence 
above and the sequence from the proband's genomic DNA below, with abnormal sequence italicized. The single base nonsense 
mutation is indicated by the arrow. Panel C shows normal LIPA cDNA sequence from a single copy cloned source derived from 
a normal individual, spanning part of exon 7, all of exon 8 and then part of exon 9. The lower part of the panel shows the 
cDNA sequence for one of the proband's alleles, in which exon 8 has been deleted in frame. This confirms that the mutation at 
the intron-exon boundary of exon 8 affected RNA splicing.
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± 0.04 mmol/L), and a decrease in TC:HDL-C ratio of
11.5% (10.4 ± 0.3 to 9.2 ± 0.5). When pooled data over
~70 months from all 19 determinations on lovastatin
were compared with diet alone, statin treatment was asso-
ciated with a further 13.5% decrease in TC (to 5.47 ± 0.42
mmol/L), a 12.6% increase in TG (to 2.24 ± 0.36 mmol/
L), a 15.9% decrease in LDL-C (to 3.98 ± 0.41 mmol/L),
an 8.7% decrease in HDL-C (to 0.63 ± 0.08 mmol/L), and
a 5.5% decrease in TC:HDL-C ratio (to 8.7 ± 0.2). Finally,
when pooled data over 12 months from all four determi-
nations on ezetimibe plus lovastatin were compared with
lovastatin monotherapy, the drug combination was asso-
ciated with a further 9.4% decrease in TC (to 4.96 ± 0.60
mmol/L), a 3.1% decrease in TG (to 2.17 ± 0.20 mmol/L),
an 15.8% decrease in LDL-C (to 3.35 ± 0.46 mmol/L), no
change in HDL-C (0.63 ± 0.08 mmol/L), and a 9.1%
decrease in TC:HDL-C ratio (to 7.9 ± 0.3). Unpaired t-tests
showed that the TC and LDL-C concentrations were signif-
icantly different for the period with lovastatin mono-
therapy compared to the period with combination
therapy (P < 0.05). Also, there were no deviations of
plasma CK and AST above the upper limit of normal for
any treatment period. Finally, liver and spleen size evalu-
ated clinically were reduced compared to baseline over the
treatment period with statin and then later statin plus
ezetimibe; specifically, while the liver edge was palpable 5
cm below the right costal margin before drug treatment it
was not palpable at the most recent clinical assessment.
Molecular genetic studies
Genomic DNA sequencing of the LIPA gene revealed that
the proband had two mutations (Figure 2). The first was a
T insertion in exon 6 at codon 178 that shifted the reading
frame (Figure 2A) and caused a premature termination at
codon 190 (FS A178-X190). The second was G>A change
at the last nucleotide of exon 8 (Q277), which resulted in
a silent mutation at the amino acid level (Figure 2B). The
patient was heterozygous for both mutations. In order to
determine the chromosomal phase of the two LIPA muta-
tions, sequencing of exon 6 and exon 8 from the
proband's mother's genomic DNA revealed that she was a
simple heterozygote for the frameshift mutation, confirm-
ing the that two mutations in the proband were on differ-
ent chromosomes. Reverse transcriptase PCR
amplification of LIPA from the proband, followed by
sequence analysis of the partial cDNA spanning exon 5
through exon 10 revealed an abnormal sequence in which
the entire exon 8 had been deleted (Figure 2C).
Discussion
The untreated lipoprotein profile of our CESD patient
revealed not only a combined hypercholesterolemia and
hypertriglyceridemia, but also a severe hypoalphalipopro-
teinemia, indicating that mutations in LIPA  are a rare
genetic cause of complex dyslipidemia. Of course, this is
in the context of numerous systemic abnormalities, specif-
ically hepatomegaly. We also showed improvement of the
plasma lipoprotein profile with low fat diet, with further
improvement with statin monotherapy and even further
improvement with the addition of ezetimibe in combina-
tion with the statin.
Lovastatin has been shown to be safe and effective in treat-
ing hypercholesterolemia over the long term in adults
[26,27]. The ~80 month treatment period for our proband
was among the longest time spans for any of our young
patients with respect to duration of statin therapy. Over
this period, the patient's hepatomegaly improved clini-
cally and the AST and CK have remained stable. The addi-
tion of ezetimibe was associated with further
improvement of plasma lipoproteins, and was also well
tolerated in combination with statin treatment.
Statins have previously been successfully used in adoles-
cents with CESD with some variability in reported efficacy
[8-14]. This may be explained by genetic heterogeneity in
response to lovastatin or by underlying differences in the
factors responsible for the hyperlipidemia [3] Statins
block the conversion of 3-hydroxymethylglutaryl-coen-
zyme A (HMGCoA) to mevalonate, a rate limiting step in
cholesterol biosynthesis. This results in an increase in the
number and activity of LDL receptors on the hepatocyte
membrane, and the rate of LDL catabolism increases. In
patients with CESD, the increased activity of the LDL
receptors theoretically could lead to increased accumula-
tion of cholesteryl esters in the liver [4]. However, Gins-
berg et al. [2] showed no change in hepatic cholesteryl
ester accumulation after 8 months of lovastatin 40 mg
daily in a 9 year old girl with CESD. Furthermore, our
patient had reduced hepatomegaly clinically, suggesting
that cholesteryl ester accumulation in the liver was
unlikely.
Our findings also suggest that ezetimibe may be a useful
treatment in patients with CESD. Ezetimibe interferes
with the normal function of the NPC1L1 gene product,
which regulates sterol absorption in the small intestine
[15-17]. This is thought to result in depletion of hepatic
cholesterol and upregulation of hepatic LDL receptors.
The mean plasma LDL-C reduction seen with ezetimibe is
~20%, and this has been remarkably consistent across
patient subgroups defined by age, gender, ethnic back-
ground and concomitant use of other lipid regulating
agents, such as statin drugs [20-25]. Inter-individual
genetic variation may also play a role in the response to
ezetimibe; for instance, a subset of individuals with a par-
ticular NPC1L1 haplotype appears to have a larger plasma
LDL-C response [28]. Combination therapy for hypercho-
lesterolemia may allow more patients to achieve target
plasma TC and LDL-C goals. We observed that coadmin-Lipids in Health and Disease 2005, 4:26 http://www.lipidworld.com/content/4/1/26
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istration of ezetimibe with lovastatin resulted in reduction
in plasma LDL-C concentration of 16% compared to lov-
astatin alone. Ezetimibe appeared to be well tolerated by
our patient and there were no reported adverse effects.
Ezetimibe added to lovastatin did not result in an increase
in muscle enzymes. In fact, serum CK (mean ± SD) actu-
ally decreased from 185 ± 156 with statin monotherapy to
120 ± 68 during combination treatment with the statin
and ezetimibe. AST levels never exceeded the upper limit
of normal at any time. The complementary mechanism of
action of ezetimibe and statins may offer a new treatment
alternative for dyslipidemia management in CESD
patients.
Methods
Genomic DNA analysis
Genomic DNA was isolated from whole blood obtained
from patients (Puregene, GentraSystem, Minneapolis,
MN). The entire coding region and intron-exon bounda-
ries of LAL gene were amplified using custom primer pairs
shown in table 1. PCR amplifications were carried out in
a 50 µl mixture containing 32 pmole of each primer, 0.2
mM of each dATP, dCTP, dGTP and dTTP, 1.5 mM MgCl2,
50 mM KCl, 20 mM Tris-HCl (pH 8.4), 2.5 units of Taq
platinum DNA polymerase (Invitrogen, Mississauga,
ON). 30 cycles were performed consisting of denaturation
at 94°C, annealing at 56°C and extension at 72°C for 30
s each, followed by extension for 10 min at 72°C. PCR
products were purified from agarose (QIAQuick Gel
Extraction Kit, Qiagen, Mississauga, ON). Direct DNA
sequence results were analyzed with an ABI automated
sequencer 3730 and were read with ABI Sequence Naviga-
tor software (both from PE Biosystems, Mississauga, ON).
Reverse transcriptase polymerase chain reaction and 
cDNA sequence analysis
Total RNA was isolated from the proband using PAXgene
Blood RNA Tube and Blood RNA Kit (Qiagen, Missis-
sauga, ON). 2.5 ml blood was used for RNA isolation
according to manufacturer's instruction. 100 ng of total
RNA was used for first strand cDNA synthesis (SuperScript
First Strand Synthesis System, Invitrogen, Mississauga,
ON). 2 µl of first strand reaction was used for amplify par-
tial cDNA sequence of the LIPA gene spanning exon 5 to
10 with primer pair 5' AAT ATG ACC TAC CAG CTT CCA,
3' GTA AGC AAA CAC ATT TTC ACA. PCR products were
gel purified, sequenced and read as described above.
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